Cancer Drug Ups Risk of Clots in Veins

Those on Avastin faced 33% increased risk of dangerous side effect

By Amanda Gardner
HealthDay Reporter

Related Encyclopedia • Acidophilus • Adenocarcinoma of the Lung and Brain Metastases • Amenorrhea • Amniocentesis More... Related Healthscout Videos What's Your Stroke IQ? Disaster Heart Attacks Teaching Old Docs New Tricks Optimistic Healing More... Related Animations • Angioplasty • Breast Reduction • Breast Self-Exam Video • Colon Cancer More... Related Drug Information • Accupril • Actonel • Altace • Avapro More... Related News Articles • Living With Less TV, More Sweat Boosts Weight Loss • Folate Levels in Pregnancy Tied to ADHD in Offspring • CDC Study Links 2 Antibiotics to Birth Defects • Sugar Shortens Life Span in Worms More...

TUESDAY, Nov. 18 (HealthDay News) -- The widely used cancer drug Avastin appears to be associated with a greater risk of developing blood clots in the veins of patients with a variety of cancers.

This risk lengthens an already long list of severe side effects associated with the drug, including clots in the artery, heart attacks, stroke and bowel perforation.

Text Continues Below

---

It has previously been recognized that Avastin caused clots in arteries, but it was unclear whether it resulted in similar problems in veins, a condition known as venous thromboembolism (VTE).

The new research, published in the Nov. 19 issue of the Journal of the American Medical Association, may indicate a need not only for prophylactic measures to reduce the risk, but also for a black box warning to be added to the package insert, the authors stated.

"Prophylactic considerations should be given for patients at high risk for VTE, and benefits/risk should be evaluated in patients who develop VTE on Avastin," added study senior author Dr. Shenhong Wu, an assistant professor of medical oncology at Stony Brook University Cancer Center, in Stony Brook, N.Y.

"A lot of clinicians have kept all along a healthy respect for [these side effects]," added Dr. John Marshall, chief of hematology/oncology at Georgetown's Lombardi Comprehensive Cancer Center in Washington, D.C. "What this study does suggest is that we should think more about prophylaxis. Do I think this has the potential to change the official language in the package insert? Yes, I do."

Avastin (bevacizumab) is the first member of a family of drugs designed to attack cancers by cutting off their blood supply. It does this by inhibiting the action of vascular endothelial growth factor (VEGF), a protein that promotes the growth of blood vessels.

Avastin was first approved in 2004 by the U.S. Food and Drug Administration for treatment of lung and colon cancer. It became controversial in 2008, when the FDA approved it for use against advanced breast cancer, despite a 5-4 vote by an advisory committee against that approval. Committee members said the drug's ability to slow tumor progression did not outweigh the damage done by side effects such as blood clots and cardiovascular problems.

Page:  1 | 2 | Next >>